Phreesia (PHR)
(Delayed Data from NYSE)
$21.37 USD
-0.59 (-2.69%)
Updated May 10, 2024 04:00 PM ET
After-Market: $21.36 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
PHR 21.37 -0.59(-2.69%)
Will PHR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PHR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PHR
Talkspace, Inc. (TALK) Reports Q1 Loss, Tops Revenue Estimates
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
PHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Stock Market News for Mar 18, 2024
Phreesia (PHR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for PHR
Top ideas in vertical software with valuations over or below 50th percentile - Baird
Phreesia’s Alicia Cowley and Natasha Vega Named to MM+M’s ‘Women to Watch’ for 2024
Phreesia Sets Release Date for Fiscal First Quarter 2025 Results
Baird reviews short interest in the vertical software space
Phreesia (NYSE:PHR): A Value Play in Healthcare Tech